BIOGRAPHIES

Pedro Cahn
Pedro Cahn

Pedro Cahn, M.D., Ph.D, is Professor of Infectious Diseases at the Buenos Aires University Medical School and Scientific Director of the Huesped Foundation. He earned his Doctor of Medicine degree from the University of Buenos Aires Medical School. Dr. Cahn has been working in infectious diseases for the last 45 years and involved in the HIV/AIDS arena since 1982. He founded the first infectious diseases unit within a public hospital in Argentina, the Infectious Diseases Division at the Juan A. Fernandez Hospital, where he has served as Division Chief and he is now Senior Consultant. He has been a member of the National AIDS Committee (Argentina) since 1988. He has been involved with international working groups and conferences on AIDS since 1989, including the 1st IAS Conference on HIV Pathogenesis and Treatment, and the XVII International AIDS Conference which he chaired. He is a Past-President of the International AIDS Society and an external advisor for UNAIDS, the World Health Organization (WHO), the Pan-American Health Organization, UNITAID, Doctors without Borders, as well as a member of the antiretroviral guidelines panel both for WHO and a former member of the guidelines panel of the International Antiviral Society-USA (IAS-USA). In 2014 Dr. Cahn received the distinction of Illustrious Citizen of the City of Buenos Aires and was awarded the Senator Domingo Faustino Sarmiento mention of Honor by the Honorable Argentine Senate. Dr. Cahn has published more than 190 peer-reviewed papers in international journals and has authored important book chapters.

Bonaventura Clotet
Bonaventura Clotet

Bonaventura Clotet, M.D., Ph.D, is Head of the Infectious Diseases Department of the Germans Trias i Pujol University Hospital, Director of the Retrovirology Laboratory IrsiCaixa Foundation, President of the Fight AIDS Foundation (Fundació Lluita contra la SIDA) and co-director of the HIVACAT program for the development of the AIDS vaccine in Catalonia, Spain. He received his MD and PhD at the Universitat Autònoma de Barcelona (UAB). At the academic level, he is associate professor of Medicine at the UAB and Chair of the Faculty of AIDS and related illnesses at the Central University of Catalonia. He is member of the steering committee of EuroSIDA (multicenter group for the study of AIDS in Europe) and he has been member of the Drug Resistance Mutations Group (IAS-USA) and of the Governing Council of the IAS. He also participates in the organizing committee and scientific committee of several international AIDS and Vaccine conferences. He is on the editorial board of AIDS Journal, HIV Medicine, Expert Review of Clinical Immunology, Future HIV Therapy and Journal of the International Association of Physicians in AIDS Care. He has received numerous awards among them the “Creu de Sant Jordi” one of the highest civil distinctions awarded the Generalitat of Catalonia and the award by the Catalan Institute of Health for his lifetime scientific career. In April 2013, he was named Doctor Honoris Causa by the University Carol Davila in Bucharest (Rumania). He has published more than 800 papers in international journals.

Madeleine Durand
Madeleine Durand

Madeleine Durand is a specialist in internal medicine, an epidemiologist and clinical researcher. Her research interests include cardio-metabolic aspects of aging with HIV infection, cardiovascular diseases, auto-immunity and pharamacology. She is the co-PI of the Canadian HIV and Aging Cohort Study. She is associate professor of Medicine in Université de Montréal, Québec, Canada

Giovanni Guaraldi
Giovanni Guaraldi

Dr Giovanni Guaraldi is a Assistant Professor of Infectious disease at University of Modena and Reggio Emilia (Italy). He is Modena university Rector Delegate for Cooperation and Development. Since the year 2000 he lead a liver and kidney transplant program for people with HIV infection at the m ultivisceral transplant centre at Policlinico of Modena. Since 2002 he runs a Metabolic Clinic for HIV infection. This tertiary level referral center offer a multidisciplinary team consultant service consisting of infectious disease physicians, nutritionists, personal trainers for physical activities, psychologists, cardiologist, nephrologists, endocrinologists and plastic surgeons for diagnosis and treatment of Non infectious Co-Morbidities. More than 4500 people are in charge of the Metabolic Clinic. He is a panel member of the European AIDS Clinical Society (EACS) guidelines on prevention and management of HIV associated co-morbidities . He has published widely on clinical aspects of HIV treatment and care.

Alan Landay
Alan Landay

Dr. Alan Landay is Professor and Chairman of the Department of Immunology/Microbiology at Rush University Medical Center in Chicago.  He has been involved in HIV research for over 35 years having performed some of the first immune evaluations of HIV infected haemophiliacs in 1982 while completing a postdoctoral fellowship at the University of Alabama, Birmingham.  Dr. Landay joined the faculty at Rush University Medical Center in 1983 and helped establish the HIV research program.  Dr. Landay served as Chair of the National Committee of Clinical Laboratory Standards Committee on Flow Cytometry which produced the first national standard on CD4 testing.  He has also served as an advisor to the College of American Pathologists, NIH and WHO on standardization of CD4 Testing and serves on the Bill and Melinda Gates Foundation Global Health Care Technologies Committee.  Dr. Landay’s current research focus is on immune pathogenesis and immune based therapy of HIV disease. He also studies HIV and aging and the role of the mucosal immune system and microbiome in HIV pathogenesis .He is past Chair of the Immunology Research Agenda Committee of the AIDS Clinical Trial Group NIH Program and he has served on the Executive Committee of the Forum for HIV Collaborative Research.  He also serves on the Office of AIDS Research HIV and Aging Committee.  He serves on NIH, AmFar, Glazer Pediatric AIDS Foundation and State of California Grant review panels and is past Chair of the NIH HIV Vaccine Study Section.  He has served as a mentor for over 15 graduate students and postdoctoral fellows who have gone on to obtain academic positions.  Dr. Landay has published over 400 peer reviewed papers focused on basic and clinical studies of HIV with an emphasis on the role of immune activation inflammation and microbiome in HIV pathogenesis and therapy

Eugènia Negredo
Eugènia Negredo

Dr. Eugènia Negredo completed the specialty of Internal Medicine at the Sant Pau Hospital, Barcelona, in 1998. She received her Ph.D. in Medicine from the Autonomous University of Barcelona, in 2002. Since 1999, Dr. Negredo works as a physician in the HIV Unit of Germans Trias i Pujol Hospital in Barcelona, and she leads the research group focused on the epidemiology, pathogenesis and treatment of different HIV- and antiretroviral-related complications. She is also Associate Professor of Universitat Autònoma de Barcelona and Universitat de Vic.

Roger Paredes
Roger Paredes

Dr. Roger Paredes, MD, PhD, is head of the Microbial Genomics Group at the irsiCaixa AIDS Research Institute and attending physician at the HIV Unit, Hospital Universitari Germans Trias i Pujol in Barcelona, Catalonia. His team has made seminal contributions to understanding the clinical relevance of minority drug-resistant HIV and X4 viruses on antiretroviral treatment outcomes and HIV disease progression, and is now using next-generation genomics to characterize the role of the human microbiome on HIV disease and inflammaging. Dr. Paredes is clinical virologist for several European HIV cohorts and advisor to the WHO HIV ResNet group.

Omar Sued
Omar Sued

He has been Director of Clinical Research of Huésped Foundation since 2012. He obtained his degree from the University of Córdoba in 1995. He specialized in Internal Medicine and University Specialist in Infectious Diseases (UBA, 2004), Master in Comprehensive Management of HIV-AIDS (University of Barcelona, ​​2003) and Doctor of Medicine (University of Barcelona, ​​2016). It has been dedicated to the care of people with HIV since 1997 in various public and private areas of Argentina and Spain, prisons and NGOs. He has worked as a consultant on HIV projects in Tanzania and as a consultant in several Latin American countries. From 2009 to 2012 he was Regional Adviser for HIV / AIDS Treatment for the Pan American Health Organization, Regional Office for the Americas of the World Health Organization, from where he supported the update of World Health Organization antiretroviral treatment guidelines in 18 countries of the region. He is a member of the Board of Directors of the Argentine Society of Infectology and the SADI Aids Subcommittee and president of the XVI National Congress of Infectology.

Cécile Tremblay
Cécile Tremblay

Cécile Tremblay is an infectious disease specialist at the University of Montreal and researcher at the CHUM Research Centre. She graduated in Université de Montréal and holds a Certificate in Medical Microbiology and Infectiology from the Royal College of Physicians and Surgeons of Canada and the College of physicians of Quebec.

She is currently the Director of the Hospital Research, Education and Care on AIDS Unit (UHRESS) of the Hospital Center of the University of Montral (CHUM) and Co-Director of the Axis -Resistance of the FRSQ-SIDA network.

Conflict of interest disclosures

Bonaventura Clotet has received research support grants, and fees as consultant and speaker from ViiV Healthcare and Merck Sharp & Dohme Corp.

Eugènia Negredo has received research support grants, and fees as consultant and speaker from ViiV Healthcare and Merck Sharp & Dohme Corp.

Roger Paredes has received research support grants and fees as consultant from ViiV Healthcare and Merck Sharp & Dohme Corp.

Pedro Cahn has received research support grants, and fees as consultant and speaker from ViiV Healthcare and Merck Sharp & Dohme Corp.

Giovanni Guaraldi has received research support grants, and fees as consultant and speaker from ViiV Healthcare and Merck Sharp & Dohme Corp.

Alan Landay has received research support grants from Merck Sharp & Dohme Corp.

Cécile Tremblay has received research support grants, and consultant  fees from ViiV Healthcare and Merck Sharp & Dohme Corp and participated in a Merck Sharp & Dohme Corp sponsored speaker’s bureau

Omar Sued has participated in ViiV advisory board in May 2017.

Madeleine Durand has disclosed no conflict of interest.